Seeyond trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,902 shares of the pharmaceutical company’s stock after selling 86 shares during the quarter. Seeyond’s holdings in Vertex Pharmaceuticals were worth $2,399,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Cordasco Financial Network bought a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $25,000. Clearstead Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $34,000. Axiom Investment Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $36,000. Deseret Mutual Benefit Administrators acquired a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $41,000. Finally, WealthShield Partners LLC grew its stake in Vertex Pharmaceuticals by 282.0% in the 2nd quarter. WealthShield Partners LLC now owns 466 shares of the pharmaceutical company’s stock valued at $43,000 after buying an additional 344 shares during the last quarter. 88.63% of the stock is currently owned by institutional investors.
In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani purchased 10,000 shares of the company’s stock in a transaction dated Thursday, August 19th. The stock was purchased at an average price of $195.65 per share, with a total value of $1,956,500.00. Following the completion of the purchase, the chief executive officer now owns 69,511 shares of the company’s stock, valued at $13,599,827.15. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.70% of the stock is owned by corporate insiders.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Thursday, July 29th. The pharmaceutical company reported $3.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.25 by $0.86. The business had revenue of $1.79 billion during the quarter, compared to the consensus estimate of $1.71 billion. Vertex Pharmaceuticals had a net margin of 29.80% and a return on equity of 29.73%. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 10.83 EPS for the current year.
A number of brokerages recently commented on VRTX. Royal Bank of Canada upped their price target on shares of Vertex Pharmaceuticals from $246.00 to $248.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and set a $210.00 target price on the stock. in a research report on Tuesday, July 6th. Piper Sandler increased their target price on shares of Vertex Pharmaceuticals from $261.00 to $323.00 and gave the stock an “overweight” rating in a research report on Friday, July 30th. TheStreet lowered shares of Vertex Pharmaceuticals from a “b” rating to a “c+” rating in a research report on Thursday, July 29th. Finally, Wolfe Research began coverage on shares of Vertex Pharmaceuticals in a research report on Monday, July 19th. They set an “outperform” rating and a $252.00 target price on the stock. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $264.70.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals, Inc is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Featured Story: Bollinger Bands
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.